

Appl. No. 09/872,702
Amendment dated July 8, 2003
Reply to Final Office Action of April 11, 2003

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

Ans E1

Ans E1

Ans E1

D

1. (currently amended) A method of modifying a polypeptide, comprising:
a) identifying at least one immunodominant epitope in a polypeptide, using
wherein the immunodominant epitope is identified by binding of the epitope to an antibody or
population of antibodies obtained from a naïve human or animal or population thereof; and
b) modifying the immunodominant epitope to reduce an immune response to the
polypeptide while retaining a substantial therapeutic activity of the polypeptide.

2. (previously amended) A method according to claim 1 wherein the polypeptide has
an amino acid sequence that has at least 80% sequence identity to a full-length native sequence or
native sequence lacking a signal sequence or an extracellular domain of an endogenous polypeptide
in the human or animal.

3. (previously amended) A method according to claim 2, wherein the polypeptide has
an amino acid sequence that has about 100% sequence identity to a full-length native sequence or
native sequence lacking a signal sequence or an extracellular domain of an endogenous polypeptide
in the human or animal.

4. (original) The method according to claim 1, wherein the polypeptide is selected
from the group consisting of human thrombopoietin, growth hormones, cytokines, receptors, and
humanized antibodies.

5. (previously amended) A method according to claim 1, wherein the animal is
selected from the group consisting of primates, cattle, pigs, poultry, and mice.

6. (original) A method according to claim 1, wherein the modification is a deletion of
at least one immunodominant epitope.

Appl. No. 09/872,702
Amendment dated July 8, 2003
Reply to Final Office Action of April 11, 2003

7. (original) A method according to claim 1, wherein the modification is a modification of at least one amino acid in the immunodominant epitope by N-glycosylation or pegylation.

8. (original) A method according to claim 1, wherein the modification is a mutation of one or more amino acids in at least one immunodominant epitope.

9. (original) A method according to claim 1, wherein the polypeptide is produced in a non human source.

10. (currently amended) A method of modifying a therapeutic polypeptide, comprising:

a) identifying at least one immunodominant epitope in a therapeutic polypeptide ~~wherein the immunodominant epitope is identified by binding by:~~

i) determining at least one epitope in the therapeutic polypeptide that binds to an antibody or population of antibodies from a naïve human or animal;

ii) and by binding determining at least one epitope on a therapeutic polypeptide that binds to an antibody or population of antibodies from the a human or the same species of animal dosed with the therapeutic polypeptide; and

iii) identifying at least one immunodominant epitope as an epitope that binds to both an antibody or population of antibodies from a naïve human or animal and to an antibody or populations of antibodies from a human or the same species of animal dosed with the therapeutic polypeptide; and

b) modifying the immunodominant epitope to reduce an immune response to the therapeutic polypeptide while retaining a substantial therapeutic activity of the therapeutic polypeptide.

Appl. No. 09/872,702
Amendment dated July 8, 2003
Reply to Final Office Action of April 11, 2003

11. (cancelled)

12. (currently amended) A method of modifying a therapeutic polypeptide, comprising:

- identifying at least one immunodominant epitope ~~or in~~ in a therapeutic polypeptide, ~~by using wherein the immunodominant epitope is identified by binding of the epitope to an antibody or population of antibodies obtained from a naive human or animal or population thereof, wherein the antibody does not substantially inhibit a therapeutic activity of the therapeutic polypeptide; and~~
- modifying the immunodominant epitope to reduce an immune response to the therapeutic polypeptide while retaining ~~a the substantial therapeutic activity of the polypeptide.~~

13. (currently amended) A method of modifying a therapeutic polypeptide, comprising:

- identifying at least one immunodominant epitope ~~or in~~ in a therapeutic polypeptide, ~~by using wherein the immunodominant epitope is identified by binding of the epitope to an antibody or population of antibodies from a naive human or animal or population thereof,~~
- selecting an immunodominant epitope that is not located in a region of the polypeptide providing a therapeutic activity of the polypeptide; and
- modifying the selected immunodominant epitope to reduce an immune response to the therapeutic polypeptide while retaining ~~a the substantial therapeutic activity of the therapeutic polypeptide.~~

14-21. (cancelled)

Appl. No. 09/872,702
Amendment dated July 8, 2003
Reply to Final Office Action of April 11, 2003

22. (currently amended) A method for selecting at least one immunodominant epitope to be modified in a polypeptide, comprising:

- a) identifying at least one epitope in the polypeptide, recognized by wherein the immunodominant epitope is identified by binding of the epitope to an antibody or population of antibodies from a naïve human or animal or population thereof and recognized by to an antibody or population of antibodies from the a human or same species of animal or population thereof dosed with the polypeptide, wherein the polypeptide has at least 80% sequence identity to an endogenous polypeptide in the human or same species of animal; and
- b) selecting at least one immunodominant epitope from the identified epitopes by determining whether the identified epitope more frequently elicits an antibody response than other epitopes in the polypeptide in the naïve population and in the population dosed with the therapeutic polypeptide.

23-29. (cancelled)

30. (currently amended) A method of modifying a nucleic acid encoding a modified polypeptide comprising:

D
D-1
In E2

- a) identifying at least one immunodominant epitope in a polypeptide, by using wherein the immunodominant epitope is identified by binding of the epitope to an antibody or population of antibodies obtained from a naive human or animal or population thereof;
- b) providing an isolated nucleic acid sequence encoding the polypeptide; and
- c) modifying the isolated nucleic acid to encode a modified polypeptide wherein the modified polypeptide has at least one change in the immunodominant epitope and wherein the change reduces an immune response to the polypeptide while still retaining a substantial therapeutic activity of the polypeptide.

Appl. No. 09/872,702
Amendment dated July 8, 2003
Reply to Final Office Action of April 11, 2003

Jul 8/03 31. (currently amended) A host cell transformed with comprising the modified isolated nucleic acid of claim 30.

32-34. (cancelled)

Ans E3 35. (currently amended) A method of modifying a polypeptide, comprising:
a) identifying at least one immunodominant epitope in a polypeptide, using wherein the immunodominant epitope is identified by binding of the epitope to an antibody or population of antibodies obtained from a naïve human or population thereof; and
b) modifying the immunodominant epitope to reduce an immune response to the polypeptide while retaining a substantial therapeutic activity of the polypeptide.

36. (previously added) A method according to claim 35, wherein the polypeptide is a polypeptide that has an amino acid sequence that has at least 80% amino acid sequence identity to a full length native sequence or native sequence lacking a signal sequence or an extracellular domain of an endogenous polypeptide in the human.

37. (previously added) A method according to claim 35, wherein the polypeptide is a polypeptide that has an amino acid sequence that has at least 85% amino acid sequence identity to a full length native sequence or native sequence lacking a signal sequence or an extracellular domain of an endogenous polypeptide in the human.

38. (previously added) A method according to claim 35, wherein the polypeptide is a polypeptide that has an amino acid sequence that has at least 90% amino acid sequence identity to a full length native sequence or native sequence lacking a signal sequence or an extracellular domain of an endogenous polypeptide in the human.

39. (previously added) A method according to claim 35, wherein the polypeptide is a polypeptide that has an amino acid sequence that has at least 95% amino acid sequence identity to a

Appl. No. 09/872,702
Amendment dated July 8, 2003
Reply to Final Office Action of April 11, 2003

full length native sequence or native sequence lacking a signal sequence or an extracellular domain of an endogenous polypeptide in the human.

40. (previously added) A method according to claim 35, wherein the polypeptide is an isolated polypeptide that has an amino acid sequence that has about 100% amino acid sequence identity to a full length native sequence or native sequence lacking a signal sequence or an extracellular domain of an endogenous polypeptide in the human.

41. (previously added) The method according to claim 35, wherein the polypeptide is selected from the group consisting of human thrombopoietin, growth hormones, cytokines, receptors, and humanized antibodies.

42. (previously added) A method according to claim 35, wherein the modification is a deletion of at least one immunodominant epitope.

43. (previously added) A method according to claim 35, wherein the modification is a modification of at least one amino acid in the immunodominant epitope by N-glycosylation or pegylation.

44. (previously added) A method according to claim 35, wherein the modification is a mutation of one or more amino acids in at least one immunodominant epitope.

45. (previously added) A method according to claim 35, wherein the polypeptide is produced in a non human source.

46. (currently amended) A method of modifying a therapeutic polypeptide, comprising:
a) identifying at least one immunodominant epitope in a therapeutic polypeptide
~~wherein the immunodominant epitope is identified by binding by:~~

Appl. No. 09/872,702
Amendment dated July 8, 2003
Reply to Final Office Action of April 11, 2003

i) determining at least one epitope in the therapeutic polypeptide that binds to an antibody or population of antibodies from a naïve human or animal population thereof;

ii) and by binding determining at least one epitope in a therapeutic polypeptide that binds to an antibody or population of antibodies from the a human or same species of animal population thereof dosed with the therapeutic polypeptide; and

iii) identifying at least one immunodominant epitope as an epitope that binds to both an antibody or population of antibodies from a naïve human or population thereof and to antibody or populations of antibodies from a human or population thereof dosed with the therapeutic polypeptide; and

b) modifying the immunodominant epitope to reduce an immune response to the therapeutic polypeptide while retaining a substantial therapeutic activity of the therapeutic polypeptide.

47. (cancelled)

48. (currently amended) A method of modifying a therapeutic polypeptide, comprising:

a) identifying at least one immunodominant epitope ~~on in~~ in a therapeutic polypeptide, ~~by using wherein the immunodominant is identified by binding of the epitope to an antibody or population of antibodies obtained from a naive human or population thereof, wherein the antibody does not substantially inhibit a therapeutic activity of the therapeutic polypeptide; and~~

b) modifying the immunodominant epitope to reduce an immune response to the therapeutic polypeptide while retaining ~~a~~ the substantial therapeutic activity of the polypeptide.

49. (currently amended) A method of modifying a therapeutic polypeptide, comprising:

Appl. No. 09/872,702
Amendment dated July 8, 2003
Reply to Final Office Action of April 11, 2003

Sub E4

- a) identifying at least one immunodominant epitope ~~or in~~ a therapeutic polypeptide, ~~by using wherein the immunodominant epitope is identified by binding to an antibody or population of antibodies from a naive human or population thereof,~~
- b) selecting the immunodominant epitope that is not located in a region of the polypeptide providing a therapeutic activity of the polypeptide; and
- c) modifying the selected immunodominant epitope to reduce an immune response to the therapeutic polypeptide while retaining a the substantial therapeutic activity of the therapeutic polypeptide.

50. (currently amended) A method of modifying a nucleic acid encoding a modified polypeptide comprising:

Sub E4

- a) identifying at least one immunodominant epitope ~~or in~~ a polypeptide, ~~by using wherein the immunodominant epitope is identified by binding to an antibody or population of antibodies obtained from a naive human or population thereof;~~
- b) providing an isolated nucleic acid sequence encoding the polypeptide; and
- c) modifying the isolated nucleic acid to encode a modified polypeptide wherein the modified polypeptide has at least one change in the immunodominant epitope and wherein the change reduces an immune response to the polypeptide while still retaining a substantial therapeutic activity of the polypeptide.

Sub E6

51. (currently amended) A host cell ~~transformed with~~ comprising the modified nucleic acid of claim 50.